The Virginia Commonwealth University (VCU) discoveries relate to non-pulmonary oxygenation, enhanced oxygen transport to tissue, and gas-based wound and tissue therapeutics.
Chris Stern, chairman and CEO of Synthetic Blood, said: “These licenses will allow our company to develop novel products with Oxycyte in combination with hydrogen peroxide. We believe these can be developed to be used in cardiopulmonary indications and for revolutionary wound treatment indications and devices.”